Search results for "Deep vein thrombosi"

showing 10 items of 28 documents

Paradoxical embolism through a patent foramen ovale from central venous catheter thrombosis: A potential cause of stroke

2020

Paradoxical embolism refers to a potential condition in which an embolus arising from a venous source crosses into the systemic circulation through a right-to-left cardiac shunt causing an arterial embolism. A 39-year-old woman carrier of a central venous catheter (CVC) without evident risk factors for stroke, developed an acute right homonymous hemianopia during hemodialysis. On neuroimaging, an infarct in the territory of the left posterior cerebral artery was demonstrated. Transesophageal echocardiography revealed a patent foramen ovale (PFO) and a large fluctuating thrombus in the right atrium on the tip of the CVC, thus allowing a diagnosis of ischemic stroke from paradoxical embolism.…

Adultmedicine.medical_specialtyArterial embolismCardioembolismmedicine.medical_treatmentEmbolismForamen Ovale Patent03 medical and health sciences0302 clinical medicineParadoxical embolismEmbolusUpper Extremity Deep Vein ThrombosisInternal medicinemedicineHumanscardiovascular diseases030212 general & internal medicineThrombusStrokebusiness.industryCardiac shuntmedicine.diseasePatent foramen ovaleStrokeNeurologyPatent foramen ovaleCardiologySettore MED/26 - NeurologiaFemaleNeurology (clinical)businessCentral venous catheterEchocardiography Transesophageal030217 neurology & neurosurgeryCentral venous catheterEmbolism ParadoxicalJournal of the Neurological Sciences
researchProduct

Comparison of heparin to citrate as a catheter locking solution for non-tunneled central venous hemodialysis catheters in patients requiring renal re…

2014

Background The incidence of acute kidney injury (AKI) is estimated at 10 to 20% in patients admitted to intensive care units (ICU) and often requires renal replacement therapy (RRT). ICU mortality in AKI patients can exceed 50%. Venous catheters are the preferred vascular access method for AKI patients requiring RRT, but carry a risk of catheter thrombosis or infection. Catheter lock solutions are commonly used to prevent such complications. Heparin and citrate locks are both widely used for tunneled, long-term catheters, but few studies have compared citrate versus heparin for patients with short-term, non-tunneled catheters. We aim to compare citrate 4% catheter lock solution versus hepar…

Catheter Obstructionmedicine.medical_specialtyCatheterization Central VenousTime Factorsmedicine.medical_treatmentHemodialysis CatheterCatheter ObstructionMedicine (miscellaneous)urologic and male genital diseasesHospitals UniversityStudy ProtocolAcute renal failureClinical ProtocolsDouble-Blind MethodRenal DialysisCitrate lockIntensive careUpper Extremity Deep Vein ThrombosisProhibitinsmedicineCentral Venous CathetersHumansPharmacology (medical)Heparin lockRenal replacement therapyCitratesProspective StudiesContraindicationbusiness.industryHeparinAcute kidney injuryAnticoagulantsEquipment DesignAcute Kidney Injurymedicine.diseasefemale genital diseases and pregnancy complicationsSurgeryCatheterIntensive Care UnitsTreatment OutcomeResearch DesignHemodialysisHemodialysisFranceCritically ill patientbusinessCatheter lockTrials
researchProduct

Serial 2-Point Ultrasonography Plus D-Dimer vs Whole-Leg Color-Coded Doppler Ultrasonography for Diagnosing Suspected Symptomatic Deep Vein Thrombosis

2008

Context Patients with suspected deep vein thrombosis ( DVT) of the lower extremities are usually investigated with ultrasonography either by the proximal veins ( 2-point ultrasonography) or the entire deep vein system ( whole- leg ultrasonography). The latter approach is thought to be better based on its ability to detect isolated calf vein thrombosis; however, it requires skilled operators and is mainly available only during working hours. No randomized comparisons are yet available evaluating the relative values of these 2 strategies. Objective To assess if the 2 diagnostic strategies are equivalent for the management of symptomatic outpatients with suspected DVT of the lower extremities.…

Malemedicine.medical_specialtyDeep veinContext (language use)VeinsSettore MED/15 - Malattie Del Sanguelaw.inventionFibrin Fibrinogen Degradation ProductsRandomized controlled triallawD-dimermedicineHumansProspective StudiesUltrasonography Doppler ColorProspective cohort studyAgedVenous ThrombosisFirst episodeLegbusiness.industrydeep vein thrombosiultrasonographyGeneral MedicineMiddle Agedmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareThrombosisSurgeryVenous thrombosismedicine.anatomical_structureD-dimerFemaleRadiologybusinessJAMA
researchProduct

Survival and recurrent venous thromboembolism in patients with first proximal or isolated distal deep vein thrombosis and no pulmonary embolism

2017

Essentials The long-term risk of recurrence and death after distal deep vein thrombosis (DVT) is uncertain. We included subjects with first proximal or isolated distal DVT (IDDVT) and no pulmonary embolism. The risk of symptomatic and asymptomatic recurrence is lower after IDDVT (vs. proximal). IDDVT may be associated with a lower long-term risk of death, especially after unprovoked DVT. SummaryBackground A few studies have focused on the risk of recurrence after first acute isolated distal deep vein thrombosis (IDDVT) compared with proximal DVT (PDVT), whereas the incremental risk of death has never been explored beyond the first 3 years after acute event. Methods Our single-center cohort …

Malemedicine.medical_specialtyDeep veinKaplan-Meier Estimate030204 cardiovascular system & hematologyLower riskGastroenterologyAsymptomaticVeinsanticoagulation; death; distal deep vein thrombosis; pulmonary embolism; venous thromboembolism; Hematology03 medical and health sciences0302 clinical medicineRecurrenceRisk FactorsdeathInternal medicinemedicineHumans030212 general & internal medicineanticoagulationAgedVenous Thrombosisbusiness.industryMortality rateHazard ratioVenous ThromboembolismHematologyMiddle Agedmedicine.diseaseThrombosisSurgeryPulmonary embolismVenous thrombosisTreatment Outcomemedicine.anatomical_structureFemaledistal deep vein thrombosismedicine.symptomPulmonary EmbolismbusinessFollow-Up StudiesJournal of Thrombosis and Haemostasis
researchProduct

Measuring functional limitations after venous thromboembolism: A call to action.

2019

The main objectives of therapeutic trials in venous thromboembolism (VTE) are to prevent recurrent VTE, major bleeding and death. While these outcomes are indeed highly relevant, they are also rare and do not fully capture the overall functional outcome of VTE patients. Importantly, functional limitations after VTE are prevalent after both deep vein thrombosis and pulmonary embolism occurring in up to 50% of patients. These post-VTE syndromes are associated with a decreased quality of life, higher risk of depressive disorders, unemployment and increased utilization of healthcare resources. Because of the major impact of functional limitations on individual patients and society as a whole, d…

Malemedicine.medical_specialtyDeep veinMann Whitney U test030204 cardiovascular system & hematologyValue-based healthcare03 medical and health sciences0302 clinical medicineQuality of life (healthcare)Postthrombotic syndromeRisk FactorsDeep vein thrombosisHealth carepulmonary hypertensionmedicineHumanscardiovascular diseasesIntensive care medicineVenous Thrombosisbusiness.industryPulmonary embolismActivities of daily livingAnticoagulantsHematologyVenous Thromboembolismmedicine.diseaseequipment and suppliesClassificationThrombosisCall to actionPulmonary embolismClinical trialmedicine.anatomical_structure030220 oncology & carcinogenesisScale (social sciences)FemalebusinessThrombosis research
researchProduct

Sex-specific differences in the presentation, clinical course, and quality of life of patients with acute venous thromboembolism according to baselin…

2021

Abstract Introduction Sex and the presence of specific provoking risk factors, along with age, influence the presentation and prognosis of venous thromboembolism (VTE). We investigated the presentation, course and quality of life in women and men with acute VTE classified according to their VTE provoking factors. Methods PREFER in VTE is an international, non-interventional registry of patients with a first episode of acute symptomatic VTE. Baseline provoking factors were classified as follows: major transient, minor transient, active cancer, and none identifiable. The primary outcome was recurrent VTE. Quality of life and treatment satisfaction were secondary outcomes. Results Of 3,455 pat…

Malemedicine.medical_specialtyEpidemiology610 Medicine & health030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineQuality of lifeRecurrenceInternal medicineDeep vein thrombosisEpidemiologyInternal MedicineMedicineHumanscardiovascular diseases030212 general & internal medicineFirst episodeSex Characteristicsbusiness.industry10031 Clinic for AngiologyAbsolute risk reductionCancerAnticoagulantsVenous Thromboembolismequipment and suppliesmedicine.diseaseSex specificNeoplasm RecurrenceRisk factorsLocal2724 Internal MedicineQuality of LifeSexFemalePresentation (obstetrics)Neoplasm Recurrence LocalbusinessVenous thromboembolism
researchProduct

Clinical course of isolated distal deep vein thrombosis in patients with active cancer: a multicenter cohort study

2017

Essentials Isolated distal deep vein thrombosis (IDDVT) is frequently associated with cancer. No study has specifically evaluated the long-term clinical course of cancer-associated IDDVT. Patients with cancer-associated IDDVT are at very high risk of symptomatic recurrence and death. We observed low rates of major bleeding during anticoagulation. SummaryBackground Although isolated distal deep vein thrombosis (IDDVT) is frequently associated with cancer, no study has specifically evaluated the long-term clinical course of IDDVT in this setting. Aim To provide data on the rate of recurrent venous thromboembolism (VTE), major bleeding events and death in IDDVT patients with active cancer. Pat…

Malemedicine.medical_specialtydistal deep vein thrombosis; mortality; neoplasm; observational study; venous thromboembolism; HematologyTime FactorsDeep veinHemorrhage030204 cardiovascular system & hematologyDisease-Free Survival03 medical and health sciences0302 clinical medicineRecurrenceRisk FactorsNeoplasmsInternal medicinemedicineHumans030212 general & internal medicineAgedProportional Hazards ModelsRetrospective StudiesVenous ThrombosisHematologybusiness.industryIncidenceClinical courseAnticoagulantsCancerdistal deep vein thrombosiVenous ThromboembolismHematologyHeparinMiddle Agedmedicine.diseasemortalityThrombosisSurgeryTreatment Outcomemedicine.anatomical_structureItalyobservational studyFemaledistal deep vein thrombosisPulmonary EmbolismbusinessVenous thromboembolismneoplasmDistal deep vein thrombosis; Mortality; Neoplasm; Observational study; Venous thromboembolism; Hematologymedicine.drugCohort studyJournal of Thrombosis and Haemostasis
researchProduct

SARS-CoV-2 infection and venous thromboembolism after surgery: an international prospective cohort study

2021

SARS-CoV-2 has been associated with an increased rate of venous thromboembolism in critically ill patients. Since surgical patients are already at higher risk of venous thromboembolism than general populations, this study aimed to determine if patients with peri-operative or prior SARS-CoV-2 were at further increased risk of venous thromboembolism. We conducted a planned sub-study and analysis from an international, multicentre, prospective cohort study of elective and emergency patients undergoing surgery during October 2020. Patients from all surgical specialties were included. The primary outcome measure was venous thromboembolism (pulmonary embolism or deep vein thrombosis) within 30 da…

Malepulmonary embolismInternationalitySettore MED/18 - CHIRURGIA GENERALEDeep veinVascular damage Radboud Institute for Health Sciences [Radboudumc 16]infectious diseasesCardiovascularSARS‐CoV‐2surgeryCOVID-19 ; SARS-CoV-2 ; deep vein thrombosis ; pulmonary embolism ; venous thromboembolismCohort StudiesPostoperative ComplicationsAnesthesiologyMedicine and Health SciencesProspective Studies610 Medicine & healthProspective cohort studyLung11 Medical and Health SciencesConfoundingHematologyMiddle AgedThrombosis17 Psychology and Cognitive SciencesCOVID-19; deep vein thrombosis; pulmonary embolism; SARS-CoV-2; venous thromboembolismPulmonary embolismCOVID-19; SARS-CoV-2; deep vein thrombosis; pulmonary embolism; venous thromboembolism.medicine.anatomical_structureCohortCOVID-19/complicationsPostoperative Complications/etiologyOriginal ArticleFemalePatient SafetyLife Sciences & BiomedicineCOVID-19; SARS-CoV-2; deep vein thrombosis; pulmonary embolism; venous thromboembolismHumanAdultmedicine.medical_specialtyAdolescentClinical Sciencesvenous thromboembolism610 Medicine & healthGlobalSurg CollaborativeVenous Thromboembolism/etiologydeep vein thrombosisNOCOVIDSurg CollaborativeYoung AdultMedicine General & InternalAge DistributionClinical ResearchCOVID‐19General & Internal MedicinemedicineHumansSex DistributionAgedScience & Technologybusiness.industrySARS-CoV-2PreventionNeurosciencesdeep vein thrombosiCOVID-19PneumoniaOdds ratioOriginal Articlesmedicine.diseaseSurgeryReconstructive and regenerative medicine Radboud Institute for Health Sciences [Radboudumc 10]Prospective StudieGood Health and Well BeingAnesthesiology and Pain MedicineHuman medicinePostoperative ComplicationCohort StudiebusinessVenous thromboembolism[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

COVID-19 Vaccine and Death: Causality Algorithm According to the WHO Eligibility Diagnosis

2021

The current challenge worldwide is the administration of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines. Even if rarely, severe vascular adverse reactions temporally related to vaccine administration have induced diffidence in the population at large. In particular, researchers worldwide are focusing on the so-called “thrombosis and thrombocytopenia after COVID-19 vaccination”. This study aims to establish a practical workflow to define the relationship between adverse events following immunization (AEFI) and COVID-19 vaccination, following the basic framework of the World Health Organization (WHO). Post-mortem investigation plays a pivotal role to support this c…

Medicine (General)medicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Clinical BiochemistryPopulation030204 cardiovascular system & hematologyArticledeep vein thrombosisAutoimmune thrombocytopenia03 medical and health sciencesautopsyR5-9200302 clinical medicinevaccinestandard protocolMedicineIntensive care medicineeducationAdverse effectdisseminated intravascular coagulationeducation.field_of_studySARS-CoV-2business.industryCOVID-19post-mortem investigationCausalityVaccinationimmune thrombocytopeniaImmunization030220 oncology & carcinogenesisvaccination campaignbusinessDiagnostics
researchProduct

Fundamental Research in Oncology and Thrombosis 2 (FRONTLINE 2): A Follow‐Up Survey

2020

Abstract Background Fundamental Research in Oncology and Thrombosis (FRONTLINE) is a global survey of physicians' perceptions and practice in the management of venous thromboembolism (VTE) in patients with cancer. Materials and Methods The present survey, FRONTLINE 2, follows the original FRONTLINE survey (published in The Oncologist in 2003) and provides insights into how physicians perceive risk of VTE in cancer and approach its prophylaxis and treatment. Results Between November 2015 and February 2016, 5,233 respondents participated, representing cancer physicians and surgeons. Most believed that less than one in five patients with any cancer might be at risk of VTE, with a slightly high…

OncologyCancer Researchmedicine.medical_specialtymedicine.drug_classmedicine.medical_treatment26030204 cardiovascular system & hematologyFondaparinuxDabigatranVenous thromboembolism • Cancer-associated thrombosis • Deep vein thrombosis • Pulmonary embolism • Central venous catheter.03 medical and health sciences0302 clinical medicineInternal medicineSurveys and QuestionnairesVenous thromboembolism • Cancer‐associated thrombosis • Deep vein thrombosis • Pulmonary embolism • Central venous cathetermedicineHumansRivaroxabanbusiness.industryAnticoagulantWarfarinCancerAnticoagulantsThrombosisVenous ThromboembolismHeparin Low-Molecular-Weightmedicine.diseasePulmonary embolismOncologySymptom Management and Supportive Care030220 oncology & carcinogenesisbusinessCentral venous cathetermedicine.drugFollow-Up StudiesThe Oncologist
researchProduct